Eisai Company Analysis
Eisai Company Analysis
$3,000.00
Pharmavitae Analytics explores Eisai’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Updated analysis and forecasts based on Q1 2017 company-reported sales.
Pharmavitae Analytics explores Eisai’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Snapshot
- 2021 outlook – Revenues will be flat, as early revenue declines from the patent expiry of Aloxi is offset by growth in the oncology portfolio.
- 2026 outlook – Topline will fall by $140m.
- Events – Lenvima expansion in oncology, and the entry of generic competition for Lyrica and Aloxi. The creation of the gastroenterology portfolio through a strategic alliance with Ajinomoto
Highlights
- From 2016–26 Eisai’s pharmaceutical revenue will decline by $140m as it fails to fully mitigate a long-term trend of declining sales.
- Eisai’s CNS offering will remain its largest therapy area.
- Eisai’s diversification into oncology will fuel mid-term growth.
- Ajinomoto alliance will help reposition Eisai’s GI portfolio in the long term.
Model Updates
- Addition of gastroenterology portfolio.
Analysis structure
Explore and visualize revenue dynamics in the Eisai’s portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections:
Company context
- How is Eisai strategically poised out to 2026?
- What are Eisai’s key strengths, weaknesses, opportunities and threats?
- What are Eisai’s key catalysts over the next four quarters?
Facts and figures
- What is Eisai’s forecasted sales performance out to 2026?
- What is the revenue trajectory of Eisai’s current top 10 products out to 2026?
- Which therapy areas will experience the largest growth and decline?
- What are the portfolio weightings of Eisai based on the lifecycle of products?
Key therapy areas
- Why will specific therapy areas will experience the largest growth and decline?
- What are the detailed competitive dynamics at play in Eisai’s important therapeutic markets?
- How is Eisai adapting to strategically to internal and external headwinds?
TABLE OF CONTENTS
5 EXECUTIVE SUMMARY
6 COMPANY CONTEXT
6 Outlook
6 Agreement with Biogen
6 Eisai’s SWOT Analysis
7 Eisai’s key events and catalysts
9 FACTS AND FIGURES
9 Eisai’s prescription pharma sales outlook
9 Eisai’s therapy area dynamics
13 Eisai’s top 10 products over 2016–26
13 Eisai’s growth drivers and resistors
17 Eisai’s launch/core/expiry analysis
19 Eisai’s financial outlook
20 Eisai’s M&A history
22 KEY THERAPY AREAS
22 Central nervous system
27 Oncology
30 Gastrointestinal
33 BIBLIOGRAPHY
LIST OF FIGURES
9 Figure 1: Eisai’s prescription pharmaceutical sales ($m) and growth rate (%), 2013–26
10 Figure 2: Eisai’s therapy area dynamics, 2016–26
13 Figure 3: Eisai’s top 10 product sales ($m), 2016–26
17 Figure 4: Eisai’s launch/core/expiry analysis, 2016–26
19 Figure 5: Eisai’s operating revenue/cost analysis ($m), 2010–22
LIST OF TABLES
11 Table 1: Eisai’s sales by therapy area ($m), 2016–26
14 Table 2: Eisai’s key products, 2016–26
18 Table 3: Eisai’s sales by launch, core, and expiry portfolio ($m), 2016–26
20 Table 4: Eisai’s financial performance, 2016–22
21 Table 5: Eisai’s key merger and acquisition deals, 2003–16
23 Table 6: Eisai central nervous system portfolio ($m), 2016–26
28 Table 7: Eisai oncology portfolio ($m), 2016–26
31 Table 8: Eisai Gastrointestinal portfolio ($m), 2016–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Dupilumab 
Sign up to the